New AdisInsight

Overview

AdisInsight is an integrated database that includes content to help you monitor and evaluate drug development globally, identify and evaluate clinical trial evidence, and manage adverse case reports.

AdisInsight enables you to...

• Discover curated, scientific and clinical content
• Build simple or complex search queries
• Create reports to support critical business decisions

![AdisInsight interface image](image-url)
Demonstration
### Advanced Search

#### Frequently Searched
- Adverse Event
- Drug Name
- Drug Class
- Full Text
- Indication

#### Other Search Criteria
- Mechanism of Action
- Organisation
- Phase
- Therapeutic Area
- Update Date

---

### All Search Criteria

| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z |
| A | Adverse Event | I | Indication | O | Organisation |
| D | Drug Class | J | Journal Name | P | Patient Count |
| E | Drug Name | L | Location | T | Therapeutic Area |
| E | EPhMRA code | M | | | | |
Advanced Search

Frequently Searched
- Adverse Event
- Drug Name
- Drug Class
- Full Text
- Indication

Mechanism of Action
- Therapeutic Area
- Update Date

All Search Criteria

Your query where
- Mechanism of Action
- Beta-blockers

Will result in approximately 114 Drugs, 31 Deals, 1,971 Safety Reports and 345 Trials

Show Results
Advanced Search

Frequently Searched
- Drug Name
- Drug Class
- Full Text
- Indication

Mechanism of Action
- Organisation
- Phase
- Therapeutic Area
- Update Date

All Search Criteria

Your query where
- Mechanism of Action
- Beta-blockers
- AND
- Indication

Cardiovascular disorders

You are getting 0 Safety Reports because your search includes Indication.
New AdisInsight

Refine Your Search

- Indication
  - Cardiovascular disorders
  - Hypertension
  - Arrhythmias
  - Glaucoma
  - Ocular hypertension

- Phase
  - Marked
  - Registered
  - Preregistration
  - Phase II
  - Phase I/III

- Location
  - Asia
  - USA
  - Europe
  - European Union
  - Japan

- Mechanism Of Action
  - Beta-adrenergic receptor antagonists

114 Drugs  31 Deals  1,971 Safety Reports  345 Trials

Showing 50 of 114 drugs

Sort by: Update date  Export

Bucindolol
Beta 1 adrenergic receptor antagonists, Beta 2 adrenergic receptor antagonists

Active Indications (Highest Phase)
- Phase II/III: Atrial fibrillation

Inactive Indications
- Discontinued: Heart failure; Myocardial infarction

Originator: Bristol-Myers Squibb  Licensed by: ARCA biopharma Inc; CPEC

Carvedilol controlled release - GlaxoSmithKline
Alpha 1 adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists

Active Indications (Highest Phase)
- Marketed: Heart failure; Hypertension; Left ventricular dysfunction

No Inactive Indications

Originator: Roche  Licensed by: GlaxoSmithKline

Bisoprolol
Beta 1 adrenergic receptor antagonists

09 Feb 2015
27 Jan 2015
Search results for Mechanism of Action: "Beta-blockers"

114 Drugs
31 Deals
1,971 Safety Reports
345 Trials

Showing 50 of 114 drugs

**Tafluprost/timolol**
Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists

**Active Indications (Highest Phase)**
Marketed: Glaucoma; Ocular hypertension

No Inactive Indications

Originator: Santen Oy; Santen Pharmaceutical | Licensed by: Merck & Co

**Bucindolol**
Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists

**Active Indications (Highest Phase)**
Phase II/III: Atrial fibrillation

09 Feb 2015
## Trial Landscape

<table>
<thead>
<tr>
<th>Indication</th>
<th>Phase</th>
<th>Countries</th>
<th>Route / Formulation</th>
<th>Developers</th>
<th>Event Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular hypertension</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>Open-angle glaucoma</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>5</td>
<td>-</td>
</tr>
</tbody>
</table>

Showing 1 to 2 of 2 related trials

## Development Status

### Summary Table

<table>
<thead>
<tr>
<th>Indication</th>
<th>Patient Segment</th>
<th>Phase</th>
<th>Countries</th>
<th>Route / Formulation</th>
<th>Developers</th>
<th>Event Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td>-</td>
<td>Marketed</td>
<td>Germany, Japan</td>
<td>Ophthalmic / Drops</td>
<td>Santen Oy, Santen Pharmaceutical</td>
<td>17 Feb 2015</td>
</tr>
</tbody>
</table>
Thank you